Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Namrata Vijayvergia"'
Autor:
Eric A. Ross, Jean-Nicolas Gallant, Efrat Dotan, Harry S. Cooper, Karen Ruth, Harold A. Harvey, Miriam Kunkel, Arthur Winer, Bora Lim, Kevin P. White, Kenneth R. Korzekwa, Namrata Vijayvergia, Edward W. Wang, Jeffrey Sivik, Steven J. Cohen, Wafik S. El-Deiry, Lanlan Zhou, Igor Astaturov, Crystal S. Denlinger
Publikováno v:
Clinical Colorectal Cancer. 20:e43-e52
Background Quinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC). This phase 1b trial evaluated the combination of quinacrine plus capecitabine in patients with treatment-refractory mCRC. Patients and Met
Autor:
Namrata Vijayvergia, Thomas L Holden
Publikováno v:
Current Colorectal Cancer Reports. 17:1-9
The currently established standard of care treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME) and adjuvant fluorouracil and oxaliplatin. The body of evidence that sup
Autor:
Kerry S. Campbell, R. Katherine Alpaugh, Alexander W. MacFarlane, Ho Man Yeung, Paul F. Engstrom, Essel Dulaimi, Arvind Dasari, Namrata Vijayvergia
Publikováno v:
Cancer Immunol Immunother
High grade neuroendocrine neoplasms (G3 NENs) are rare aggressive tumors with limited treatment options. Twenty-one previously treated patients with metastatic extra-pulmonary G3 NENs were treated with pembrolizumab. Baseline tumor samples were asses
Autor:
Sonali Agrawal, William H. Ward, Caitlin R. Meeker, Efrat Dotan, Sandeep Aggarwal, Namrata Vijayvergia, Elizabeth Handorf, Jeffrey M. Farma, Sunil Adige, Crystal S. Denlinger
Publikováno v:
Journal of the National Comprehensive Cancer Network. 18:HSR20-076
Autor:
Taymeyah Al-Toubah, Steven J. Cohen, Nicole Ross, Arvind Dasari, Efrat Dotan, Paul F. Engstrom, Michael J. Hall, Melissa M. Runyen, Namrata Vijayvergia, R. Katherine Alpaugh, Jonathan R. Strosberg, Crystal S. Denlinger, Daniel M. Halperin, Mengying Deng, Samuel Litwin
Publikováno v:
British Journal of Cancer
Background Metastatic high-grade neuroendocrine neoplasms (G3NENs) have limited treatment options after progression on platinum-based therapy. We addressed the role of Pembrolizumab in patients with previously treated metastatic G3NENs. Methods Two o
Autor:
Arash Kardan, Thomas J. Giordano, Thorvardur R. Halfdanarson, Jennifer A. Chan, Lawrence S. Blaszkowsky, Christopher H. Lieu, Pamela Brock, Anthony P. Heaney, Boris W. Kuvshinoff, Satya Das, Whitney S. Goldner, Al B. Benson, Cindy Hochstetler, Beth Lynn, Heloisa P. Soares, Craig R. Sussman, Fouad Kandeel, Jin He, Daniel M. Halperin, Emily K. Bergsland, Jonathan R. Strosberg, Nataliya Uboha, Sajid A. Khan, Terence Z. Wong, Kimberly A. Miller, Michael C. Soulen, Martin J. Heslin, Venu G. Pillarisetty, Manisha H. Shah, Paxton V. Dickson, Nikolaos A. Trikalinos, Namrata Vijayvergia, Shagufta Shaheen, Diane Lauren Reidy, Sarimar N Agosto Salgado, Paul T. Fanta
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 19(7)
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paraga
Autor:
Elizabeth Handorf, Michael J. Hall, Joshua E. Meyer, Caitlin R. Meeker, Elin R. Sigurdson, Maureen V. Hill, William H. Ward, Crystal S. Denlinger, Igor Astsaturov, Thomas L Holden, Matthew Zibelman, Margret B. Einarson, Efrat Dotan, R. Katherine Alpaugh, Sanjay S. Reddy, Namrata Vijayvergia, Jeffrey M. Farma
Publikováno v:
JCO Clin Cancer Inform
PURPOSE Performance status (PS) is a subjective assessment of patients' overall health. Quantification of physical activity using a wearable tracker (Fitbit Charge [FC]) may provide an objective measure of patient's overall PS and treatment tolerance
Autor:
Arvind Dasari, Namrata Vijayvergia
Publikováno v:
Curr Treat Options Oncol
Ongoing advances in our understanding of neuroendocrine tumor (NET) biology, genetics, and immunology, will continue to expand the availability of targeted therapies, thus improving the outcomes of patients. Well-differentiated neuroendocrine tumors
Autor:
Khadija Cheema, Shannon M Lynch, Angel G Ortiz, Lavanya Nagappan, Elizabeth Handorf, David Madnick, Efrat Dotan, Matthew Moccia, Kristen Sorice, Namrata Vijayvergia
Publikováno v:
J Gastrointest Oncol
BACKGROUND: Pancreatic adenocarcinoma (PCA) incidence is higher in Black compared to White patients. Beyond race, neighborhood socioeconomic status (nSES) may also inform disparities. However, these effects on metastatic pancreatic adenocarcinoma (mP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::951e168e8712fb34fd41f28fd8ee392f
https://europepmc.org/articles/PMC7475328/
https://europepmc.org/articles/PMC7475328/
Autor:
Adriana Albini, Nikolaos Papanikolaou, Caterina Marchiò, Federica Massa, Gaia Gatti, Mauro Papotti, Angelica Sonzogni, Enrica Bresaola, Fiorella Calabrese, Giuseppe Pelosi, Sergio Harari, Namrata Vijayvergia, Luisella Righi
Publikováno v:
Translational Lung Cancer Research. 6:513-529
Neuroendocrine tumors of the lung (Lu-NETs) embrace a heterogeneous family of neoplasms classified into four histological variants, namely typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lun